Monoclonal Antibodies Used in Combination for HCC

home / case-based-roundtable-series / monoclonal-antibodies-used-in-combination-for-hcc

This roundtable series examines combination therapy for treatment-naive patients with unresectable or metastatic hepatocellular carcinoma, as discussed by key opinion leaders and participants at virtual live events.

Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC

Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC

Stacey Stein, MD
May 1st 2024

Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.